Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?
- PMID: 33583906
- PMCID: PMC8381185
- DOI: 10.2169/internalmedicine.6807-20
Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?
Keywords: abpm; allergic bronchopulmonary mycosis; aspergillosis; aspergillus; asthma; cystic fibrosis.
Comment in
-
Reply to "Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?".Intern Med. 2021 Aug 1;60(15):2521. doi: 10.2169/internalmedicine.6952-20. Epub 2021 Feb 15. Intern Med. 2021. PMID: 33583909 Free PMC article. No abstract available.
Comment on
-
Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan.Intern Med. 2021 May 1;60(9):1443-1450. doi: 10.2169/internalmedicine.6217-20. Epub 2020 Nov 16. Intern Med. 2021. PMID: 33191330 Free PMC article.
References
-
- Dhooria S, Sehgal IS, Muthu V, Agarwal R. Treatment of allergic bronchopulmonary aspergillosis: from evidence to practice. Future Microbiol 15: 365-376, 2020. - PubMed
-
- Agarwal R, Dhooria S, Sehgal IS, et al. A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 52: 1801159, 2018. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
